

AD \_\_\_\_\_

Award Number: DAMD17-03-1-0348

TITLE: Predicting Drug Concentration Distribution Using a  
Validated Finite Element Model in Locally Advanced Breast  
Cancer

PRINCIPAL INVESTIGATOR: Benjamin Viglianti  
Mark W. Dewhirst, D.V.M., Ph.D.

CONTRACTING ORGANIZATION: Duke University  
Durham, North Carolina 27710

REPORT DATE: July 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20041118 040

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2004		3. REPORT TYPE AND DATES COVERED Annual Summary (13 Jun 03-12 Jun 04)
4. TITLE AND SUBTITLE Predicting Drug Concentration Distribution Using a Validated Finite Element Model in Locally Advanced Breast			5. FUNDING NUMBERS DAMD17-03-1-0348	
6. AUTHOR(S) Benjamin Viglianti Mark W. Dewhirst, D.V.M., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Duke University Durham, North Carolina 27710  E-Mail: blv3@duke.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words)  The long-term objective of this study is to develop methods to predict the concentration-distribution of liposomally encapsulated doxorubicin in locally advanced breast cancer. Chemotherapy is frequently ineffective in shrinking these tumors to the point that they can be removed due to heterogeneity in drug delivery. One method to improve the uniformity of drug delivery is use local hyperthermia with thermally sensitive liposome, which releases their contents rapidly under local hyperthermia. In pre-clinical studies, this formulation was superior to non-thermally sensitive liposomes with HT. The difference was directly proportional to the tissue drug concentration. We have developed a novel MR imageable liposome formulation. This liposome contains the chemotherapeutic drug, but also the MR contrast agent manganese. We have developed and validated a MR compatible heating device and obtained temperature distributions. We have shown the uptake of the liposomes and their content release under hyperthermic conditions using MRI in a rodent model. The calculated concentration within the tumor using MRI has been validated with direct tissue measurements by histology sections using fluorescence microscopy. These measurements demonstrate that MRI can be used to non-invasively measure the concentration distribution of chemotherapy drugs delivered with these liposomes. This ability to monitor liposomal/drug delivery and/or content release in real time could allow for development of treatment strategies to improve intratumoral homogeneity of drug concentration presumably increasing treatment efficacy.				
14. SUBJECT TERMS Liposomes, MRI, Drug Delivery, Mathematical Modeling, Hyperthermia				15. NUMBER OF PAGES 26
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## Table of Contents

Cover	1
SF 298	2
Introduction	4
Results/Discussion	5
Key Research Accomplishments	9
Reportable Outcomes	10
Conclusions	12
References	13
Appendices	14

## Introduction:

Local control of stage III locally advanced breast cancer (LABC) is typically poor with conventional therapy. Current treatments, such as chemotherapy and/or radiation therapy are frequently ineffective in shrinking these tumors to the point that they can be removed. This inability to treat LABC has been attributed to perfusion limitations that these tumors present. e of the most successful ways to overcome this perfusion barrier is to use local hyperthermia (HT). HT causes vasodilation, increasing liposomal delivery to the tumor.

We hypothesize by that applying the FE (FE) method to generate a model, using an individual's Gd-DTPA contrast uptake, anatomy, and temperature dependence of vessel permeability and liposomal drug release as input functions, we can predict liposomal drug-concentration distribution in a rat tumor model.

We believe that the efficacy of liposomal chemotherapy treatment is related to perfusion distribution in each tumor and that the ability to predict drug concentration-distribution will determine which patients are most likely to benefit from this treatment. If this method accurately predicts drug concentration-distribution is validated in this rat tumor model, it will allow for direct translation of our method to human trials.

## Results/Discussion:

The results of this past year are highly relevant for the development of methods to optimize and monitor liposomal drug delivery and content release. The ability to obtain serial measurements non-invasively will allow determination of tissue pharmacokinetics and assessment of intratumoral heterogeneity with respect to drug delivery.

The in-vitro results (Figure 1) illustrate that these liposome formulations are imageable in their intact form and that content release can be observed in LTSLs upon heating.




Figure 1: Baseline relaxivity measurements made at 25 °C. Samples were then heated and subsequently cooled to illuminate hysteresis in relaxivity measurements. (a) Signal intensity vs. repetitions time (msec) between rf excitation pulses at 29.9 °C for (■) water, (□) 0.25 mM, (▲) 0.5 mM, (Δ) 1.0 mM, (●) 2.0 mM, and (◻) 4.0 mM MnSO<sub>4</sub> + DOX (a). (b) 1/T<sub>1</sub> (sec<sup>-1</sup>) (as derived from (a)) vs. MnSO<sub>4</sub> concentration (mM) at 29.9 °C. Slope of this regression is termed relaxivity and represents the change in 1/T<sub>1</sub> as a function of MnSO<sub>4</sub> concentration. (c) Relaxivity (mM\*sec)<sup>-1</sup> vs. temperature (°C) is shown for (▼) free MnSO<sub>4</sub> + empty LTSL, (●) MnSO<sub>4</sub>, (◻) free MnSO<sub>4</sub> + DOX, and (▲) MnSO<sub>4</sub> in NTSL. Relaxivity decreased linearly with increasing temperature for free MnSO<sub>4</sub> but increases with increasing temperature for encapsulated MnSO<sub>4</sub>. (d) Relaxivity (mM\*sec)<sup>-1</sup> vs. temperature (°C) is shown for (▼) MnSO<sub>4</sub> in LTSL and (●) MnSO<sub>4</sub> + DOX in LTSL. Linear regressions from (c) are also shown. LTSL ± DOX relaxivity follows the trend of NTSL encapsulated MnSO<sub>4</sub>, until the transition temperature is reached. When the transition temperature is reached (39-40 °C) rapid increase in relaxivity occurs as MnSO<sub>4</sub> is released. With additional heating and subsequent cooling the LTSL ± DOX behaves like MnSO<sub>4</sub> + LTSL from (c).

The hysteresis observed in relaxivity when the LTSLs were heated and then cooled below their transition temperature serves as confirmation of content release.

In-vivo results demonstrated that release of contents was seen in response to local hyperthermia (Figure 2).<sup>1</sup>




Figure 2: MRI axial image results of rats with transplanted flank fibrosarcomas treated with (a) LTSL with HT, (b) LTSL without HT, (c) NTSL with HT, and (d) NTSL without HT from 0 to 90 minutes. (a) The LTSL with HT (slice #5 from figure #4) shows rapid signal enhancement that remains through the experiment at the periphery of the tumor. This enhancement is heterogeneous but localized only within the tumor. (b) LTSL without HT shows less intense but more uniform signal enhancement in tumor. That peaks at 5 minutes and then fades as clearance of LTSL from the vasculature occurs. (c) NTSL with HT has an intermediate result between the LTSL with and without HT. There is heterogeneous distribution of the NTSL as with the LTSL with HT (a), but the distribution penetrates to the catheter. (d) The NTSL without HT shows minimal enhancement at 5 minutes, which reflects the presence of liposomes in the vasculature. The flank tumor is indicated along with the heating catheter, venous vessels, and unheated muscle

This conclusion was based on four observations.<sup>1</sup> (1) A unique pattern of peripheral MR signal enhancement seen in LTSL + HT experiments that was absent from the other three groups, (2) dynamic contrast imaging with Gd-DTPA showed that the perfusion pattern flows from the periphery to the center (data not shown), (3) the temperature at the periphery of the tumor was at the transition temperature for the liposome<sup>1</sup>, (4) and the enhancement in the tumor periphery remained after heating was discontinued, indicating that HT did not cause hysteresis effects that would confound interpretation of the results. Additionally, the results of the in-vivo study showed that the liposomes were imageable within the drug dose used (10 mg/kg) for therapy.<sup>1</sup>

Further results demonstrated the feasibility of using MRI to measure drug concentration distributions, *in vivo* (Figure 3).




Figure 3: (a-c) Signal intensity ratio (SIR) of LTSL + HT, LTSL alone, and NTSL + HT. LTSL and NTSL + HT had the (■) TE, (●) TN, and (Δ) Vessel regions measured. LTSL alone had only (■) TE and (Δ) Vessel regions measured. All the vessel ROIs had similar time course and TE regions showed consistent enhancement over the course of the experiment. There was difference in maximal TE values and overall time course due to liposomal content release and thermally mediated liposome accumulation. (d) Calibration curve of fluorescence signal intensity versus DOX concentration. The linear regression was used for measurement of DOX concentration in histology sections (see text). (e) SIR ROI measurement versus DOX concentration. There is a linear relationship between SIR value and increasing DOX concentration measured directly with fluorescence microscopy. (f) DOX concentration measured with MRI versus DOX concentration fluorescence measurement. The DOX concentration from the MRI was determined by the  $T_1$  shortening caused by the  $Mn^{2+}$  containing liposomes. This yielded an  $Mn^{2+}$  concentration within the tissue voxel using the *in-vitro* determined temperature dependent relaxivity, which was then converted to DOX concentration by the loading ratio and encapsulation volume of the liposome. The relationship between MRI determined DOX concentration versus DOX concentration fluorescence measurement was linear. Each data point in e and f represent an animal's ROI (TE or TN) mean measurement. Each measurement had a minimum of 3 histological ROI measurements and 5 slice MRI ROI measurements.

The ability of a method to evaluate the delivery of chemotherapy drugs would have multiple benefits. Access to such data would allow for real time monitoring of tissue pharmacokinetics, which would allow for better precision of individualized pharmacokinetics/dynamics in individual patients. This would allow for: 1) modification of treatment variables to improve the uniformity of drug delivery and 2) provide a means to select patients most likely to benefit from a particular drug treatment.

#### Future Directions:

In the future, experiment designed to demonstrate the ability to direct drug delivery (a chemo dose painting scheme such as is done in radiation therapy) could allow direct treatment of tumors to be improved. Additionally, further studies using HPLC to measure drug

concentration as a further validation of the MR tool would be helpful to bring this technique to the clinical environment.



**Key Research Accomplishments:**

- Developed and validated an MR compatible local hyperthermia heating device for murine flank tumors
- Validated the ability of liposomes to serve as a contrast agent in-vitro
- Demonstrated the ability of liposomes to server as a contrast agent in-vivo and the ability to use hyperthermia to cause increase liposome/drug accumulation and/or cause liposomal content release
- Validated MRI as a tool to non-invasively measure liposomal drug concentration distribution

## Reportable Outcomes:

### Degrees/Education:

- Ph.D. in Biomedical Engineering: "Chemodosimetry of In-vivo Tumor Liposome/Drug Concentration using MRI," Benjamin L. Viglianti
- Accepted to Duke University School of Medicine for entry in the fall of 2004 semester

### Papers (Accepted)

- "In-Vivo Monitoring Of Tissue Pharmacokinetics Of Liposome/Drug Using MRI: Illustration Of Targeted Delivery," Benjamin L. Viglianti, Sheela A. Abraham, Charles R. Michelich, Pavel S. Yarmolenko, James R. MacFall, Marcel B. Bally, Mark W. Dewhirst: In Press: Magnetic Resonance in Medicine 51:1153-1162 (2004)
- "Role Of Hyperthermia In Regional Alkylating Agent Chemotherapy," Abdel-Wahab, OI, Grubbs, E, Viglianti, BL, Cheng, TY, Ueno, T, Ko, S, Rabbani, Z, Curtis, S, Pruitt, SK, Dewhirst, MW, Tyler, DS., Clinical Cancer Research (In Press)

### Papers (Draft/Submitted)

- "Chemodosimetry Of In-Vivo Tumor Liposome/Drug Concentration Using MRI," (Draft Research Article) Benjamin L. Viglianti, Charles R. Michelich, Sheela A. Abraham, O. Michael Colvin, Pavel S. Yarmolenko, James R. MacFall, Marcel B. Bally, Mark W. Dewhirst
- "Importance Of Measuring Macroscopic Heterogeneous Tumor Drug Delivery In The Treatment Of Locally Advance Cancer," (Draft Review Article) Benjamin L. Viglianti, O. Michael Colvin, Pavel S. Yarmolenko, Mark W. Dewhirst
- "Regional Differences In Lung Function As Determined By Hyperpolarized Helium Magnetic Resonance Imaging Used To Predict Normal Tissue Complication Properties In Radiation Induced Lung Damage," (Submitted Research Article) E. Ward, L. Hedlund, W. Kurylo, B. Viglianti, C. Wheeler, M. Dewhirst, L. Marks and Z. Vujaskovic  
Departments of Radiation Oncology & Radiology, Duke University Medical Center
- "Comparison Of Glucose And Lactate Concentration Distributions With Perfusion And Hypoxia In R3230Ac And Fibrosarcomas Of The Fischer 344 Rat," (Draft Research Article) Schroeder T, Viglianti BL, Peltz C, Asopa S, Vujaskovic Z, Dewhirst MW

## Conferences

- "Role of Hyperthermia in Regional Alkylating Agent Chemotherapy," Abdel-Wahab, O, Grubbs, E, Cheng, TY, Viglianti, BL, Ueno, T, Curtiss, SR, Pruitt, SK, Colvin, OM, Dewhirst, MW, Tyler, DS *Annals Of Surgical Oncology*, 11 (2): S79-S80 Suppl. S FEB 2004
- "Regional Differences In Lung Function As Determined By Hyperpolarized Helium Magnetic Resonance Imaging Used To Predict Normal Tissue Complication Properties In Radiation Induced Lung Damage," ASTRO October 2004 (Alanta, Ga.), E. Ward , L. Hedlund, W. Kurylo, B. Viglianti, C.Wheeler , M. Dewhirst, L. Marks and Z. Vujaskovic Departments of Radiation Oncology & Radiology, Duke University Medical Center
- "Chemodosimetry Of In-Vivo Tumor Liposome/Drug Concentration Using MRI," ASTRO October 2004 (Alanta, Ga.), Benjamin L. Viglianti, Charles R. Michelich, Sheela A. Abraham, O. Michael Colvin, Pavel S. Yarmolenko, James R. MacFall, Marcel B. Bally, Mark W. Dewhirst
- "Spatial Relationship Between Tumor Perfusion And Endogenous Glucose Distribution," Schroeder T, Richardson R, Larrier N, Viglianti B, Rabbani ZN, Vujaskovic Z, Dewhirst MW, 12th International Congress of the Radiation Research Society (ICRR) in Brisbane, Australia, Aug 17-22, 2003

### Conclusions:

The ability of a method to evaluate the delivery of chemotherapy drugs would have multiple benefits. Access to such data would allow for real time monitoring of tissue pharmacokinetics, which would allow for better precision of individualized pharmacokinetics/dynamics in individual patients. This would allow for: 1) modification of treatment variables to improve the uniformity of drug delivery and 2) provide a means to select patients most likely to benefit from a particular drug treatment.

References:

1. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med 2004;51(6):1153-62.

See publication list in "Reportable Outcomes" section

Appendices.....

- “In-Vivo Monitoring Of Tissue Pharmacokinetics Of Liposome/Drug Using MRI: Illustration Of Targeted Delivery,” Benjamin L. Viglianti, Sheela A. Abraham, Charles R. Michelich, Pavel S. Yarmolenko, James R. MacFall, Marcel B. Bally, Mark W. Dewhirst: In Press: Magnetic Resonance in Medicine 51:1153–1162 (2004)
- Resume

# In Vivo Monitoring of Tissue Pharmacokinetics of Liposome/Drug Using MRI: Illustration of Targeted Delivery

Benjamin L. Viglianti,<sup>1</sup> Sheela A. Abraham,<sup>2,3</sup> Charles R. Michelich,<sup>1</sup>  
Pavel S. Yarmolenko,<sup>4</sup> James R. MacFall,<sup>5</sup> Marcel B. Bally,<sup>2,3</sup> and Mark W. Dewhirst<sup>1,4\*</sup>

The purpose of this study was to determine if  $\text{MnSO}_4$ /doxorubicin (DOX) loaded liposomes could be used for in vivo monitoring of liposome concentration distribution and drug release using MRI. In vitro results show that  $T_1$  shortening correlates with  $\text{MnSO}_4$  concentration. Using a temperature-sensitive liposome formulation, it was found that  $\text{MnSO}_4$  release significantly shortened  $T_1$ . This feature, therefore, suggests that content release can also be measured with these  $\text{MnSO}_4$ -loaded liposomes. The feasibility of monitoring this drug delivery and release-imaging agent was shown in a murine tumor model. Upon tumor heating, nonthermally sensitive liposomes selectively but heterogeneously accumulated in the tumor region. The thermally sensitive liposomes showed a clear pattern of accumulation at the periphery of the tumor, concordant with the release temperature of this formulation (39–40°C). This liposome contrast agent has potential for use with hyperthermia by providing individualized monitoring of tissue drug concentration distribution during or after treatment. This would allow for: 1) modification of treatment variables to improve the uniformity of drug delivery, and 2) provide a means to select patients most likely to benefit from this liposomal drug treatment. Additionally, the drug-loading method used for this liposome is applicable to a wide range of drugs, thereby broadening its applicability. The method is also applicable to other liposomal formulations with triggered release mechanisms. *Magn Reson Med* 51: 1153–1162, 2004. © 2004 Wiley-Liss, Inc.

**Key words:** hyperthermia; chemotherapy; pharmacokinetics; liposomes

Effective cancer chemotherapy depends on delivery of drugs to cells at cytotoxic concentrations. Due to inherent perfusion limitations in tumors, delivery of drugs may be hindered (1). However, aside from using radiolabeled drugs and nuclear medicine scans (2), methods to measure drug concentration distributions noninvasively and at

therapeutic concentrations have not been reported. In this article we present an approach that can monitor liposomal drug concentration distributions as well as drug release by using a novel  $\text{MnSO}_4$ -doxorubicin (DOX) formulation. Doxorubicin is classified as a cytotoxic anthracycline antibiotic isolated from cultures of *Streptomyces peucetius* var. *caesius*. It consists of a naphthacenequinone nucleus linked through a glycosidic bond and amino sugar (daunosamine). The molecule is amphoteric, containing acidic functions in the ring phenolic groups and a basic function in the sugar amino group. It binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix. It has also been shown to bind with cell membranes as well as plasma proteins (3).

We show that this liposome can be used to monitor drug delivery and liposomal release in a murine flank tumor model. The liposomes can be visualized outside the reticulo-endothelial system (RES), thereby making this approach practical for imaging outside the liver and spleen. The basis for imaging is the presence of  $\text{MnSO}_4$  in the interior of the liposomes, which is used to load DOX (4). This method of loading uses the metal concentration gradient (4). It is believed that two DOX molecules are coordinated to each  $\text{Mn}^{2+}$  atom within the liposome (4).

The relaxivity of Mn is similar to that of Gd, thereby making this liposome potentially suitable as a contrast agent (5–7). Other approaches have been used to image liposomes (8,9), but none have used a liposome that is a dual drug delivery and imaging vehicle. Prior MRI-based reports have focused on obtaining images in the RES (9–14), which tends to concentrate liposomes following intravenous administration. When metal ions are retained inside liposomes, MR signal intensity is relatively unaffected (13,15). Shortening of  $T_1$ , for example, depends on interaction between metal ions and water (16). Because water cannot easily cross the lipid membrane except with specialized lipid formulations designed to be relatively unstable (15,16), signal intensity changes are low (13). An alternative has been to attach paramagnetic metals to the outer liposome surface (13,15). These surface attached contrast agents have shown  $T_1$  shortening essentially equivalent to that of free ions.

Prior studies have shown that hyperthermia (HT) (40–42°C) can increase liposomal uptake in tumors (1,17–19). Thus, to demonstrate that liposome accumulation and drug release can be observed, we compared the MR signal intensity of  $\text{MnSO}_4$ -DOX loaded into two types of liposomes under in vitro and in vivo conditions, with and without heating: 1) a nonthermally sensitive formulation

<sup>1</sup>Department of Biomedical Engineering, Duke University, Durham, North Carolina.

<sup>2</sup>Advanced Therapeutics-Medical Oncology, BC Cancer Agency, Vancouver, Canada.

<sup>3</sup>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

<sup>4</sup>Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

<sup>5</sup>Department of Radiology, Duke University Medical Center, Durham, North Carolina.

Grant sponsor: DOD Breast Cancer Research Program; Grant number: DAMD17-03-1-0348; Grant sponsor: NIH/NCI Grant numbers: CA42745; NIH/NCRR P4105959; NIH/NCI R24 CA092656.

\*Correspondence to: Mark W. Dewhirst, Dept. of Radiation Oncology, Duke University Medical Center, 201 MSRB Box 3455, Research Drive, Durham, NC 27705. E-mail: dewhirst@radonc.duke.edu

Received 29 April 2003; revised 5 January 2004; accepted 7 January 2004.

DOI 10.1002/mrm.20074

Published online in Wiley InterScience (www.interscience.wiley.com).

© 2004 Wiley-Liss, Inc.

(NTSL), and 2) a low-temperature sensitive liposome (LTSL) formulation that releases contents within seconds of reaching its transition temperature (39.5–40°C) (20).

## MATERIALS AND METHODS

### Liposome Materials

Doxorubicin hydrochloride (DOX) (Faulding Quebec, Canada) was purchased from the British Columbia Cancer Agency. 1,2 Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2 dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (MSPC), and 1,2 distearoyl-sn-glycero-3-phosphoethanolamine-N-(21) were obtained from Avanti Polar Lipids (Alabaster, AL). Cholesterol (Chol), Sephadex G-50, and all other chemicals were obtained from the Sigma Chemical Co. (St. Louis, MO).

### Preparation of Liposomes

Liposomes were made from either DSPC/Chol (55:45) (mol/mol), DPPC-DSPE-PEG<sub>2000</sub> (95:5) (mol/mol), DPPC-MSPC-DSPE-PEG<sub>2000</sub> (90:10:4) (mol:mol) and were prepared by the extrusion methods. Lipids, at the indicated ratios, were dissolved in a chloroform-methanol mixture. Solvent was removed under a gentle stream of nitrogen gas followed by placement under a high vacuum for at least 4 hr to remove residual solvent. Dried samples were hydrated (such that the final lipid concentration was ~100 mg/mL) with 300 mM MnSO<sub>4</sub> adjusted to pH 3.5 by addition of hydrochloric acid. Lipid hydration was performed at 55°C for ~30 min. The multilamellar vesicles were extruded 10 times through stacked polycarbonate filters of 0.1 and 0.08 µm pore size at 55°C using a water-jacketed Extruder (Northern Lipids, Vancouver, Canada) (4). The mean size distribution of all liposome preparations was determined using a Nicomp Submicron Particle Sizer Model 270 (Pacific Scientific, Santa Barbara, CA) operating at 632.8 nm and was determined to have average size diameter of 100–120 nm (22). Phospholipid was quantitated using the Fiske and Subbarow phosphate assay (23). Briefly, 700 µL of 70% perchloric acid was added to lipid samples and heated to 180–200°C for 2 hr until samples were colorless. Samples were cooled and 700 µL of Fiske reagent and 7 mL of ammonium molybdate were added. Samples were subsequently reheated to 100°C for 20 min. Samples were cooled to room temperature and absorbance was read at 820 nm.

### Preparation of Ion Gradients for Doxorubicin Encapsulation

Large unilamellar liposomes in the indicated buffers were fractionated on Sephadex G-50 columns (1 mL samples were placed on columns with at least a 20 mL column bed) equilibrated with 300 mM Sucrose/20 mM HEPES (N-(23) piperazine-N'-[2-ethanesulfonic acid]) buffer at pH 7.5. The manganese sulfate procedure for doxorubicin loading was modified from Abraham et al. (4). Following formation of the salt gradient as described above, liposome lipid concentration was adjusted to 10 mg/mL and DOX was added to achieve a drug-to-lipid ratio (wt:wt) of 0.05:1 at

37°C. It is likely that Mn<sup>2+</sup> is coordinated to the oxygens associated with the C5, C6, and C11 and C12 positions of the DOX molecule. Qualitatively, accumulation of DOX into the liposomes can be observed by a color change from orange-red (free DOX) to dark royal purple for complexed DOX (peak absorbance changes from 550 nm to 480 nm) (4). The accumulation of DOX into liposomes was determined by removing 100 µL aliquots and separating unencapsulated from encapsulated drug on 1 mL Sephadex G-50 (medium) spin columns equilibrated with the appropriate buffer. The concentration of DOX in the excluded fraction was determined by measuring absorbance (at 480 nm) of a solution containing the sample, adjusted to 100 µL with SHE, to which 900 µL of 1% Triton X-100 was added. Prior to assessing absorbance at 480 nm, the sample was placed in a >90°C water-bath until the cloud point of the detergent was observed. Liposome lipid concentrations were determined by using the phosphate assay as described above.

### Sample Solution Formation

Liposomes had their concentration converted to an equivalent MnSO<sub>4</sub> molarity using the molecular weight of the lipid and an assumption of a 1.2 µL/mmol<sub>lipid</sub> encapsulation volume commonly used to characterize liposome volume from concentration (22). Consequently, a 1-mg/mL lipid concentration with 300 mM MnSO<sub>4</sub> encapsulated yielded an MnSO<sub>4</sub> solution concentration of 0.437 mM for DPPC-MSPC-DSPE-PEG<sub>2000</sub> and 0.592 mM for DSPC/Chol assuming full liposome content release occurred. All experiments were standardized to the equivalent MnSO<sub>4</sub> concentration assuming complete content release occurred.

### Manganese Sulfate Control Stock Solutions

Three control stock solutions of manganese sulfate (MnSO<sub>4</sub>·H<sub>2</sub>O), free DOX, and MnSO<sub>4</sub>·H<sub>2</sub>O in a molar ratio of 0.902:1 (DOX:Mn), and MnSO<sub>4</sub>·H<sub>2</sub>O combined with empty thermally sensitive liposomes were used to simulate conditions when the contents had been released. These solutions, along with intact nonthermally sensitive and thermally sensitive liposome solutions containing MnSO<sub>4</sub>/DOX, were then diluted to concentrations from 0.25–8 mM. The solutions were placed in 5 mL NMR tubes cut to a three-inch length.

### In Vitro MRI Scans

All MRI experiments were performed at the Center for In Vivo Microscopy at Duke University in a 2 T 30-cm bore diameter magnet (Signa, GE Medical Systems, Milwaukee, WI). Temperature control in the bore was achieved with an automatic feedback control unit that was initially designed for maintaining temperature of laboratory animals (24). Each experiment had six to eight sample tubes, contained within an exposed sample holder, and placed inside a 3.81-cm birdcage coil. Temperatures on the heating apparatus were chosen at random, the temperature controller was set for each, and bore equilibration occurred within 10 min. A series of T<sub>1</sub>-weighted images was then taken in the axial plane with a field of view of 5 cm at an echo time



of 8 ms and TR of 20, 33.3, 66.6, 150, 316, 633, and 1266 ms. Between six and eight temperature points were measured. Each experiment was repeated three times with independently formulated reagents. Liposomes were tested sequentially with a minimum of two measurements below-above and back below the transition temperature for the LTSL (39.5–40°C). The NTSLs were tested in the same manner. If hysteresis were observed this would indicate that the contents had been released.

### In Vivo Experiments

#### Animal Model

A transplantable rat fibrosarcoma (FSA) tumor line used for this study was originally developed by subcutaneous injection of the carcinogen, methylcholanthrene, into Fischer 344 rats (25). The tumor line does not grow in vitro, so it is maintained by serial transplantation. Tumors were allowed to grow to 17–19 mm diameter before use. Animals were kept in standard housing with regular light and dark cycles. They were provided with access to water and food ad libitum. All procedures were approved by the Duke University Animal Care and Use Committee.

#### Heating Method and Determination of Temperature Distribution

Rats were anesthetized with pentobarbital (Nembutal, 50 mg/kg, IP) and a 16 G catheter was placed through the center of the tumor. The core temperature of the rats was maintained with a rectal temperature-regulated heating pad. Heated water ( $50 \pm 0.1^\circ\text{C}$ , 1.8 ml/s) was passed through the catheter to heat the surrounding tissue. The surface temperature of the catheter was  $6^\circ\text{C}$  cooler than the temperature of the heated water. Temperature profiles were measured with a k-type 33.5-gauge hypodermic thermocouple (Omega Probes) in four rats with tumors of 17–19 mm diameter after tumors reached steady state temperature (20–30 min). Measurements were located in three orthogonal planes to the heating catheter; one in the central plane and the other two  $\pm 2$  mm from the center. Each plane had four measurement tracks taken  $\pm 2$  and 4 mm from the centerline of the tumor defined by the catheter. The thermocouple was inserted to a depth of 13 mm and retracted every 1 mm, yielding  $4 \times 13$  measurements per plane. The tracks were taken in random order; the measurements within each plane were averaged and converted to a radial distance from the catheter. This yielded 26 radial measurements from 2–9 mm for each plane. The results for each were then fitted to the radial 1D steady state heat transfer equation using Gauss-Newton nonlinear regression implemented on MATLAB (MathWorks, Natick, MA).

The heating profile in the MR unit was measured in three rats. Five thermometer locations were monitored (excluding the rectal thermometer used for core temperature regulation): 1) the air stream; 2) intradermal, perpendicular to the air stream direction; 3) the tumor at the catheter surface; 4) 2.5 mm away from the catheter; and 5) at the base of the tumor adjacent to underlying muscle. The results were also fitted to the radial 1D SS heat transfer

equation, as described above, but using a different set of boundary conditions, as described in the Results.

#### MRI Scan Protocol

Rats were anesthetized with an IP injection of sodium methohexital (Brevital) 45 mg/kg. Atropine sulfate was given IP (0.35 mg/kg) to prevent mucous secretion in the airways. An endotracheal tube (16–18 gauge intracath) was inserted and the rats were mechanically ventilated with isoflurane (1–3%). ECG electrodes were placed on the footpads and a rectal thermistor was used to monitor body temperature and control the feedback-heating device (24). A catheter was placed through the center of the tumor and heated water was passed through it to provide heating, as described above. Tumors were heated for 15–20 min to reach thermal steady state before liposome injection. The rats were administered an IV dose of 200 mg/ml liposomes loaded with 0.05:1 DOX/liposome (wt:wt) yielding 10 mg/kg of DOX.

During MRI scans, heating water was doped with 0.25 M  $\text{MnSO}_4$  to prevent flow image artifacts through  $T_2$  shortening (5,7). Spoiled gradient recalled echo acquisition was used with a TR of 23 ms, echo time of 1.4 ms, and flip angles of 2, 5, 8, 10, 12, 33, 46, and  $60^\circ$  for the initial  $T_1$ -weighted image. Subsequent drug uptake scans were performed at a  $33^\circ$  flip angle. 3D volume images, 16 slices (12 useable) 1.3 mm thick, were taken with a 6 cm field of view yielding an in-plane pixel size of  $234 \times 234 \mu\text{m}$ . 1NEX (single image) was used for the first 20 min and 4NEX (four image averaging) was used for the remainder of the experiment for improved signal-to-noise. The numbers of subjects imaged were: 1) LTSL + HT ( $n = 3$ ); 2) LTSL alone ( $n = 3$ ), 3) NTSL + HT ( $n = 3$ ), and 4) NTSL alone ( $n = 2$ ).

#### Image Analysis

The MATLAB (MathWorks) software program was used for all image analysis.

#### In Vitro Experiments Image Analysis

Images were analyzed by selecting a region of interest in the center of each sample tube and measuring average signal intensity. Intensity data were fit using nonlinear least-squares data fitting governed by the Gauss-Newton method, to obtain a  $T_1$  for each concentration tested. Reciprocal  $T_1$  data were plotted as a function of concentration and fitted to a linear regression, yielding relaxivity ( $\text{mM} \cdot \text{sec}^{-1}$ ) as the slope. Relaxivity was plotted as a function of temperature.

#### Image Analysis Methods for In Vivo Studies

##### Signal Intensity Ratio

In vivo signal intensity ratio (SIR) analysis for LTSL  $\pm$  HT was done by selecting regions of interest (ROIs) (tumor enhancing, tumor nonenhancing, or muscle region) in each particular slice (26). The mean signal intensities of ROIs at each time point were calculated as the average over all slices within the experiment. Signal intensity of each ROI was normalized at each time point to the average




FIG. 1. Baseline relaxivity measurements made at 25°C. Samples were then heated and subsequently cooled to illuminate hysteresis in relaxivity measurements. **a:** Signal intensity vs. repetitions time (msec) between RF excitation pulses at 29.9°C for (■) water, (○) 0.25 mM, (▲) 0.5 mM, (△) 1.0 mM, (●) 2.0 mM, and (□) 4.0 mM MnSO<sub>4</sub> + DOX. **b:**  $1/T_1$  (sec<sup>-1</sup>) (as derived from **a**) vs. MnSO<sub>4</sub> concentration (mM) at 29.9°C. Slope of this regression is termed relaxivity and represents the change in  $1/T_1$  as a function of MnSO<sub>4</sub> concentration. **c:** Relaxivity (mM<sup>-1</sup>sec<sup>-1</sup>) vs. temperature (°C) is shown for (▼) free MnSO<sub>4</sub> + empty LTSL, (●) MnSO<sub>4</sub>, (□) free MnSO<sub>4</sub> + DOX, and (▲) MnSO<sub>4</sub> in NTSL. Relaxivity decreased linearly with increasing temperature for free MnSO<sub>4</sub> but increases with increasing temperature for encapsulated MnSO<sub>4</sub>. **d:** Relaxivity (mM<sup>-1</sup>sec<sup>-1</sup>) vs. temperature (°C) is shown for (▼) MnSO<sub>4</sub> in LTSL and (●) MnSO<sub>4</sub> + DOX in LTSL. Linear regressions from **c** are also shown. LTSL ± DOX relaxivity follows the trend of NTSL encapsulated MnSO<sub>4</sub>, until the transition temperature is reached. When the transition temperature is reached (39–40°C) rapid increase in relaxivity occurs as MnSO<sub>4</sub> is released. With additional heating and subsequent cooling the LTSL ± DOX behaves like MnSO<sub>4</sub> + LTSL from **c**.

signal intensity of the muscle ROI yielding the SIR for that particular animal and region. This normalization method was chosen because LTSL and NTSL do not extravasate in muscle, and therefore serves as an internal control (17,19). The SIR for each tumor region was then averaged across animals in each group. The resulting mean values ( $\pm$ SEM) were plotted as a function of time. A tumor nonenhancing region was not present in the LTSL alone group because this showed uniform enhancement

#### Radial Signal Distribution

Radial analysis of the MR data (RSD) facilitated comparison with the radially symmetric temperature distribution. RSD was performed by calculating the mean and standard error of the mean of the signal intensity for each pixel as a function of radial distance from the center axis of the heating catheter. The data are reported as the mean and

standard error of the mean of the signal intensity of pixels with like radial distances. The analysis was performed separately for each slice and time point.

## RESULTS

### In Vitro Experiments

In vitro experiments were performed to determine the concentration- and temperature-dependence of  $T_1$  shortening. Signal intensity resulting from proton spin realignment to the main magnetic field after excitation from repetitive RF pulses was measured. The signal received is dependent on  $T_1$  and the repetition times (TR) between RF pulses. The dependency of signal on TR is illustrated in Fig. 1a for an MnSO<sub>4</sub> liposome-DOX formulation measured over a range of drug concentrations ( $T = 29.9^\circ\text{C}$ ). The data were fit to Eq. 1 to obtain relative proton density

(PD), spin-lattice relaxation time constant ( $T_1$ ), and baseline noise ( $C$ ) for each concentration/temperature combination:

$$\text{Signal} = PD(1 - \exp(-TR/T_1)) + C. \quad [1]$$

The rate of rise of signal vs. TR increases with  $\text{Mn}^{2+}$  and drug concentration, due to  $T_1$  shortening (Fig. 1a). Changes in the asymptotic value of each curve, PD, are governed by the number of protons in each sample and by the effects of  $T_2$ . There is a linear relationship between the reciprocal of  $T_1$  ( $1/T_1$ ) and the  $\text{MnSO}_4$  concentration. The slope of this line is the "relaxivity" ( $\text{mM} \cdot \text{sec}^{-1}$ ) (6) (Fig. 1b).

Relaxivity changed as a function of temperature, but this relationship was quite different for free  $\text{MnSO}_4 \pm \text{DOX}$  and the NTSL (Fig. 1c).  $\text{MnSO}_4 + \text{empty LTSL}$  and free  $\text{MnSO}_4 \pm \text{DOX}$  exhibited decreased relaxivity with increased temperature, presumably due to increased thermal motion of  $\text{H}_2\text{O}$  and Mn, which limits the interaction of  $\text{Mn}^{2+}$  with  $\text{H}_2\text{O}$  (5,7).  $\text{MnSO}_4 + \text{DOX}$  and  $\text{MnSO}_4 - \text{DOX}$  had identical relaxivity profiles, indicating that DOX, at a concentration expected to be seen in vivo, has no effect on relaxivity of  $\text{MnSO}_4$  in solution. In contrast, relaxivity of NTSL  $\pm \text{DOX}$  increased as temperature was raised. At elevated temperatures, permeability of the liposome bilayer increases to both water and  $\text{Mn}^{2+}$ . It is known that water permeability is much greater than that observed for ions: thus, we anticipate that water exchange will be much faster than  $\text{Mn}^{2+}$ . The inverted temperature dependence is therefore probably due an increase in water exchange across the lipid bilayer (16,27). The relaxivity measurements were taken at sequentially increasing followed by decreasing temperatures, and there was no hysteresis seen indicating that  $\text{Mn}^{2+}$  remained encapsulated.

Linear regressions for relaxivity as a function of temperature were obtained for all in vitro samples (Fig. 1c).  $\text{MnSO}_4 + \text{LTSL}$ ,  $\text{MnSO}_4$ , and NTSL  $\pm \text{DOX}$  had slopes  $\pm \text{SE}$  of  $-0.166 \pm 0.023$ ,  $-0.082 \pm 0.003$ , and  $0.064 \pm 0.005$  ( $\text{mM} \cdot \text{sec}^{-1} \cdot ^\circ\text{C}^{-1}$ ) and intercepts  $\pm \text{SE}$  of  $13.67 \pm 0.087$ ,  $7.28 \pm 0.12$ , and  $-1.41 \pm 0.18$  ( $\text{mM} \cdot \text{sec}^{-1}$ ), respectively. These results are similar to previous results reported for free  $\text{MnCl}_2$  and comparable to other liposome formulations using Gd loaded into liposomes and/or surface-bound (10–12,27). For comparison, Gd-DTPA (Magnevist) has a relaxivity of  $\sim 4\text{--}4.5$  ( $\text{mM} \cdot \text{sec}^{-1} \cdot ^\circ\text{C}^{-1}$ ) (13) at physiological temperatures.

Relaxivity measurements for LTSL showed a complex temperature relationship (Fig. 1d). The measurements were taken below and above the gel to liquid phase transition temperature for this formulation ( $39.5\text{--}40^\circ\text{C}$ ) (20). Measurements started below the transition temperature, raised beyond the transition, and then as the solutions were cooled below the transition (see arrows, Fig. 1d). During the initial heating period, LTSL had relaxivity values similar to those of the NTSL. When the phase transition temperature for LTSL was approached, however, relaxivity dramatically increased to levels nearly equivalent to those for free  $\text{MnSO}_4 + \text{empty LTSL}$ . This was expected as content release from the LTSL occurs within seconds of reaching the transition temperature (20). Once liposomal contents were released, further heating showed decreased

relaxivity, consistent with behavior of free  $\text{MnSO}_4$  in solution. Relaxivity increased during subsequent cooling in a manner parallel to  $\text{MnSO}_4 + \text{empty LTSL}$ . The relaxivity of  $\text{MnSO}_4$  loaded LTSL, postrelease, was  $-0.157 \pm 0.017$  ( $\text{mM} \cdot \text{sec}^{-1} \cdot ^\circ\text{C}^{-1}$ ), which is the same as that of  $\text{MnSO}_4 + \text{empty LTSL}$  at  $-0.166 \pm 0.023$  ( $\text{mM} \cdot \text{sec}^{-1} \cdot ^\circ\text{C}^{-1}$ ). However, the intercepts for LTSL and the  $\text{MnSO}_4 + \text{empty LTSL}$  are somewhat different, suggesting that the liposomes did not release all of their contents, as reported previously (20).

#### Characterization of Temperature Distribution From Local Hyperthermia Device

The MRI-compatible heating device (Fig. 2a) yielded a radially oriented thermal profile in vivo, which was hottest near the catheter wall and decreased radially toward the tumor periphery (Fig. 2b). The data were fit to the radial 1D steady-state heat transfer equation in Eq. 2, which is governed by the thermal conductivity of the tissue ( $k$ ) and its internal heat generation ( $Q$ ):

$$T(r) = \frac{Q}{4k} r^2 + C_1 \ln(r) + C_2. \quad [2]$$

The temperature profile data were fit using nonlinear regression yielding  $0.0202 \pm 0.0034^\circ\text{C}/\text{mm}^2$ ,  $-3.464 \pm 0.1397^\circ\text{C}/\ln(\text{mm})$ , and  $43.574 \pm 0.1357^\circ\text{C}$  for  $Q/4k$ ,  $C_1$ , and  $C_2$ , respectively.

In the imaging experiments, the bore of the magnet had an elevated ambient air temperature of  $36\text{--}39^\circ\text{C}$ , while in the laboratory the temperature is typically  $21\text{--}23^\circ\text{C}$ . The elevated ambient air temperature maintained the animal's body temperature in the MRI, using a feedback hot air system (24). The increased air temperature reduced heat loss, affecting the thermal boundary conditions on the tumor. This resulted in a different thermal profile than the one measured in the laboratory. Because of the space limitations and the presence of the magnetic field in the MRI device, it was not possible to completely measure the thermal profile with a micromanipulator.

However, some manual measurements were made in the MRI. These measurements were combined with those made in the laboratory to estimate the temperature distribution of the tissue when placed in the magnet. Thermocouple measurements were made at: 1) the intradermal surface of the tumor, 2) the heating catheter surface, 3) the tumor tissue 2.5–3 mm from the catheter, 4) muscle underlying the tumor, and 5) the heated air stream. Tumor temperatures ranged from  $44\text{--}39.5^\circ\text{C}$  (catheter and skin, respectively; Fig. 2d).

The thermal profile within the bore of the magnet was calculated using data from Fig. 2b and Eq. 2. The thermal properties of the tumor ( $k$  and  $Q$ ) were derived from room air measurements and were assumed to remain constant between the two heating environments. Using Eq. 2, the integration constants  $C_1$  and  $C_2$  were calculated with the data from the boundary condition measurements taken when the animals were in the MRI device (Fig. 2c).

The predicted thermal profile (Fig. 2d) in the MRI shows good agreement with the independent measurements taken for this configuration that were not used for the simulation (Fig. 2d). The predicted thermal data are highly




FIG. 2. **a:** Cartoon of MRI compatible local hyperthermia device. **b:** Radial temperature measurements (■) of four animals. (—) Nonlinear regression fit using the steady state 1D radial heat transfer equation. **c:** Temperature profile within the MRI of (Δ) heating water within the catheter, (○) rectal temperature of the rat, (●) surface temperature of the catheter (tumor side), (□) tumor surface temperature at the skin, (▲) muscle temperature (undemeath the tumor), and (■) tumor (2.5 mm from the catheter). **d:** Nonlinear regression fit for the temperature profile in the MRI (—) using the boundary conditions from **c** and the physical properties obtained from **b**. (---) Nonlinear regression fit using the steady state 1D radial heat transfer equation.

relevant to the MR results, as described below. Importantly: 1) Local HT treatment of the tumor was achieved, while maintaining a constant rectal temperature that was below the transition temperature of the LTSL (Fig. 2c); 2) The temperature at the periphery of the tumor was estimated to be  $\geq 39.5^{\circ}\text{C}$ , which is near the transition temperature of the LTSL; 3) Steady state heating was reached after 15–20 min (Fig. 2c), indicating that at the time of liposome injection temperatures were stable.

#### In Vivo Imaging

Sixteen slice (12 useable) 3D volume images were obtained at an in-plane resolution of  $234 \times 234 \mu\text{m}$  and a slice thickness of 1.3 mm. Comparison of LTSL + HT, LTSL alone, NTSL + HT, and NTSL alone from 0–90 min is shown in Fig. 3. In the first row of Fig. 3 the tumor margin is labeled along with the heating catheter, vessels, and unheated muscle. For LTSL + HT, rapid signal enhancement occurred at the tumor periphery, which remained elevated until the end of the experiment. LTSL alone showed relatively homogenous signal enhancement that peaked at 5 min and then began to decline. NTSL + HT showed heterogeneous signal enhancement that increased throughout the experiment. NTSL alone showed marginal, but detectable, enhancement in the tumor and normal tissue at 5 min postinjection. All other time points were equivalent to background.

#### Quantitative Image Analysis

##### Signal Intensity Ratio (SIR)


Four ROIs were selected for image analysis: a tumor-enhancing region (TE), a tumor-nonenhancing region (TN), unheated muscle, and vessel. The signal intensities of the ROIs and vessel were measured for each slice. An example of these data is shown in Fig. 4a. Signal intensity data were normalized to the muscle signal to yield SIR.

Vessel SIR for LTSL  $\pm$  HT rapidly increased after liposome injection, reaching a peak at 2.5 at 3–4 min (Fig. 4b). SIR then began to decrease, reflecting clearance of liposomes from the vasculature. TE regions showed immediate and substantial increases in SIR values that were equivalent to vessel SIR values. These values remained elevated at 2.25 after 15–20 min (Fig. 4b). In contrast to the TE region, the TN region showed slow increase in SIR, rising from 0.75 at 3 min to 1.1 after 60 min of heating (Fig. 4b). The slow increase in TN regions suggests that free Mn was diffusing into this region from the surrounding TE regions. The initial drop in the SIR in the TN regions was caused by the brief initial rise in muscle signal shortly after LTSL injection, which reflected the presence of circulating liposomes.

The vessel SIR of LTSL alone reached a peak value of 2.5 at 3 min (Fig. 4c), similar to the SIR in the LTSL + HT case (Fig. 4b). The vessel SIR decreased after reaching the peak, but did not return to a value of 1 by the end of 60 min, suggesting that the LTSL circulate longer without HT than with HT (Fig. 4c). The TE region increased from a baseline of 0.75 to a peak of 1.25 by 6 min (Fig. 4c). The SIR then slowly decreased and plateaued at a value of 1.1. The initial increase in SIR probably reflects delivery of liposomes to the tumor via perfusion. The sustained elevated value is evidence of liposomal accumulation in the tumor due to extravasation. TN regions were not found in the LTSL alone group (Fig. 3).

The vessel SIR of NTSL alone reached peak values of 2.75–3.0 at 5 min (Fig. 4d), similar to the LTSL + HT and NTSL + HT cases (Fig. 4b,c). SIR also decreased after reaching the peak, but did not return to a value of 1 during the heating procedure (Fig. 4d). The TE region increased from a baseline of 0.75 throughout the experiment to a value of 1.4 by 60 min (Fig. 4d). This continuous rise in SIR probably reflects liposome extravasation. TN regions of the tumor remains fairly constant, with a slight rise 5 min

FIG. 3. MRI axial image results of rats with transplanted flank fibrosarcomas treated with (a) LTSL with HT, (b) LTSL without HT, (c) NTSL with HT, and (d) NTSL without HT from 0–90 min. **a:** The LTSL with HT (slice 5 from Fig. 4) shows rapid signal enhancement that remains through the experiment at the periphery of the tumor. This enhancement is heterogeneous but localized only with in the tumor. **b:** LTSL without HT shows less intense but more uniform signal enhancement in tumor. That peaks at 5 min and then fades as clearance of LTSL from the vasculature occurs. **c:** NTSL with HT has an intermediate result between the LTSL with and without HT. There is heterogeneous distribution of the NTSL as with the LTSL with HT (a), but the distribution penetrates to the catheter. **d:** The NTSL without HT shows minimal enhancement at 5 min, which reflects the presence of liposomes in the vasculature. The flank tumor is indicated along with the heating catheter, venous vessels, and unheated muscle



postinjection. This rise is not significant, but does correspond to the peak SIR seen in the vessels.

#### Radial Signal Distribution Method

This method was devised to facilitate comparison of the signal enhancement data with the radial temperature distribution during heating. An example of this method is shown for one LTSL + HT experiment. RSD was calculated for LTSL with HT from Fig. 3 (Fig. 5a–c). RSD was constant across the tumor at time = 0 (Fig. 5a). At 5 min postinjection (Fig. 5b), the RSD showed significant signal increase at the tumor periphery. At 60 min RSD was still elevated at the tumor periphery but the intensity elevation broadened inward toward the center of the tumor (Fig. 5c).

From the results shown in Fig. 3d, the temperature at the periphery of the tumor is  $\sim 39.5^{\circ}\text{C}$ , which is in the range of the transition temperature for this liposome (20). The *in vitro* data from this study verifies that the transition temperature is in this range (Fig. 2d). Consequently, content release from the liposome is the most likely explanation for the increase in signal intensity at this location. We can rule out the possibility that the increase in RSD was due to elevated temperature because the signal intensity remained elevated even after the temperature of the tumor was allowed to return to baseline (data not shown).

#### DISCUSSION

The results of this study are highly relevant for the development of methods to optimize and monitor liposomal

drug delivery and content release. The ability to obtain serial measurements noninvasively will allow determination of tissue pharmacokinetics and assessment of intratumoral heterogeneity with respect to drug delivery.

The *in vitro* results illustrate that these liposome formulations are imageable in their intact form and that content release can be observed in LTSLs upon heating. The hysteresis observed in relaxivity when the LTSLs were heated and then cooled below their transition temperature serves as confirmation of content release.

It is known that these liposomes do not release all of their contents, which is probably the reason the LTSL +  $\text{Mn}^{2+}$  have a higher relaxivity than  $\text{Mn}^{2+}$  loaded liposomes that were heated to release their contents (20). Additionally, the results suggest that there is an interaction between the  $\text{Mn}^{2+}$  and the LTSL upon heating. This interaction is seen in comparing the increased relaxivity of  $\text{Mn}^{2+}$  and LTSL above free  $\text{Mn}^{2+}$ . Although the nature of the interaction is unknown, it could be due to partial binding of the  $\text{Mn}^{2+}$  cation with the phospholipid head groups on the liposomes serving as the anion. This coordination would reduce the Brownian motion of  $\text{Mn}^{2+}$ , thereby increasing its interaction with water. This would raise the relaxivity (5).

The results of the study show that the liposomes are imageable within the drug dose used (10 mg/kg) for therapy. Although drug release was not measured directly in this study, it has been shown that DOX encapsulated in this liposome formulation with a pH gradient loading method is released when the transition temperature of the




FIG. 4. **a:** Signal intensity as a function of time of LTSL with HT from Fig. 3. Signal for the (□) muscle, (■) tumor-enhancing region (TE), (●) tumor nonenhancing region (TN), and (△) vessel are shown. **b:** Signal intensity ratio (SIR) for LTSL with HT for the (■) TE, (●) TN, and (△) vessel. There is rapid increase in both the vessel and TE SIR. However, the TE SIR remains elevated though the experiment, indicating that accumulation and/or content release is occurring at the tumor site. Signal enhancement remained after cooling (see text). The vessel SIR decreases after reaching a maximal value 3 min postinjection. The TN region shows minimal increase in SIR through the course of the experiment. This could be caused by diffusion of liposome contents from the area of high concentration to the TN region. **c:** SIR values for the LTSL without HT for the (■) TE and the (△) vessel region are shown. The vessel SIR increases in the same manner as the LTSL with HT experiments. SIR of the TE region increases over the same time frame as the LTSL + HT. The ratio remains relatively low, compared with LTSL + HT, but it does not return to baseline by 60 min. This indicates that accumulation of liposomes is occurring. **d:** SIR values for the NTSL with HT for the (●) tumor nonenhancing region (TN), (■) tumor enhancing region TE, and the (△) vessel region are shown. Vessel SIR increases in the same manner as the LTSL with HT and LTSL without HT experiments. SIR of the TE region increases over the experiments, indicating liposome extravasation. The TN region does not enhance. Signal intensity was averaged over 12 slices (error bars in a). SIR was calculated using the ratio of these averages. The data plotted were obtained by averaging SIRs obtained from three animals (error bars in b,c, and d).

liposome is reached (4,20). In addition, we verified that temperature-dependent drug release occurs from this formulation in independent *in vitro* experiments (data not shown) (4,20). Additional studies are ongoing to compare  $Mn^{2+}$  MR signal distribution to drug concentration. This is the foundation for a second article.

*In vivo* release of contents was also seen in response to local hyperthermia. This conclusion is based on four observations: 1) A unique pattern of peripheral MR signal enhancement seen in LTSL + HT experiments that was absent from the other three groups; 2) dynamic contrast imaging with Gd-DTPA showed that the perfusion pattern flows from the periphery to the center (data not shown); 3) the temperature at the periphery of the tumor is at the

transition temperature for the liposome (20); and 4) the enhancement in the tumor periphery remained after heating was discontinued, indicating that HT did not cause hysteresis effects that would confound interpretation of the results.

The lack of signal enhancement in the center of the tumor is not likely due to central necrosis or damage from the heating catheter. Our experiments with LTSL alone and NTSL + HT have shown that the heating catheter and local HT do not adversely affect the perfusion of the FSA tumor, respectively, since we see signal enhancement next to the catheter in these cases. Additionally, relatively homogenous vascular density has been observed in this tumor type and H&E staining of these tumors after treatment




FIG. 5. **a:** RSD analysis for LTSL with HT, slice 5 from Fig. 4/5 is shown at  $t$  equals 0 min. **b,c:** RSD analysis for 5- and 60-min time points, respectively. From **a** the signal is constant throughout the radius of the tumor. Five minutes after liposome injection (**b**) there is significant signal enhancement seen at the periphery of the tumor (also seen in Fig. 4/5). This signal enhancement is present at 60 min postinjection (**c**), but the signal enhancement begins to progress toward the center of the tumor.

indicates lack of central necrosis (Fig. 6). The implications of the enhancement pattern seen in the LTSL + HT is that homogenous drug delivery might be difficult, since the kinetics of liposomal content release is significantly shorter than the liposomal circulation time within the tumor (20). Consequently, the liposomes have their contents depleted by the time they reach the center. This release pattern might be used in an advantageous manner, targeting the periphery of the tumor where the neovascularization is present if the liposomes are loaded with vascular targeting agents.

This imaging method can also be used to monitor liposome accumulation in tumors outside the RES. Liposome extravasation is known to occur in tumors as a result of large endothelial gaps (1,28). This lack of vascular integrity is believed to be due to the immature nature of the tumor microcirculation (1). This property is one of the major methods used to target liposomal directed therapy (1,17,19), and is shown here with the increase in SIR of LTSL in the absence of HT. The fact that SIR does not



FIG. 6. Typical H&E staining of a cryosection of tumor excised at the end of an imaging experiment. There is no necrosis in the section, further supporting the conclusion that the peripheral distribution of signal enhancement in the LTSL + HT group is due to enhanced drug release from the liposomes, as opposed to decreased vascularity, as might occur iatrogenically from the presence of the catheter.

return to baseline at the end of these experiments is evidence that liposomal extravasation and retention must have occurred in the tumor.

HT is known to increase endothelial gap sizes of tumor microvessels, improving liposome accumulation (1,17,19). The HT device used for this study provided a reproducible thermal profile that was well characterized, yielding local HT in the temperature range needed to increase extravasation (1,17,19) and content release (20). The effect of improved extravasation and accumulation with HT is shown in the NTSL + HT experiments compared to NTSL alone. In the former case signal remained elevated after 60 min, whereas persistent signal enhancement was not seen with NTSL alone.

Several methods have previously been used to image liposomal drug delivery (2,8,9,11,12,14–16,27,29,30). Successful imaging of liposomal drug delivery should yield data with the following characteristics: 1) high signal-to-noise ratio (S/N) at pharmacologically relevant concentrations; 2) a signal-based parameter that can be related to drug concentration; and 3) high spatial and temporal resolution. Finally, the ideal agent for clinical application would also be one that provides imaging and therapy in the same vehicle.

PET has excellent sensitivity for detection of radiolabeled compounds and tracer amounts of radiolabeled substances can be administered to obtain quantitative data (8). However, spatial resolution is significantly sacrificed compared to other methods. CT imaging provides excellent spatial resolution but requires a contrast agent (i.e., iodine) that can be loaded into liposomes (2). Also temporal resolutions may be inferior to PET or MRI, where multiple images/min are easily acquired (2). A limitation to both PET and CT is that they cannot provide signal that reflects physical changes in the condition of the drug carrying liposome, such as would occur when contents are released.

Our formulated liposomes and choice of imaging modality (MRI) provides solutions to these problems: 1) The imaging agent (Mn) is inherent to the drug loading method for this liposome and the signal obtained is dependent on whether it is encapsulated or in free solution; 2) The liposomes provide reasonable MR S/N at pharmacologi-

cally relevant concentrations (18); and 3) Good temporal resolution can be obtained.

Suitability as a dual MR contrast and drug delivery agent also requires that the contrast agent be nontoxic systemically with respect to the cytotoxic drug as well as the  $Mn^{2+}$  that will be released. The imaging was conducted using the maximally tolerated liposomal DOX dose of 10 mg/kg, which fulfills the first criterion. The corresponding Mn dose is 78.3  $\mu\text{mol/kg}$ , which is 30% of the single dose  $LD_{50}$  of  $Mn^{2+}$  (272  $\mu\text{mol/kg}$ ) (10). Thus, it is unlikely that  $Mn^{2+}$  will be toxic, but additional studies need to be done to clarify this point. Alternatively, one could use other divalent paramagnetic cations that are less toxic as drug loading agents.

This imaging technique could also be applied to the evaluation of liposomal formulations that release contents under other types of triggers, such as pH (31). This ability to monitor liposomal/drug delivery and/or content release in real time could allow for development of treatment strategies to improve intratumoral homogeneity of drug concentration.

## REFERENCES

- Kong G, Dewhirst MW. Hyperthermia and liposomes. *Int J Hyperthermia* 1999;15:345-370.
- Bhatnagar A, Hustinx R, Alavi A. Nuclear imaging methods for non-invasive drug monitoring. *Adv Drug Deliv Rev* 2000;41:41-54.
- Holland JF, Frei E (eds.). *Cancer Medicine* 6th ed, vol. 1-2. Hamilton, Ontario: BC Decker; 2003.
- Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally M. Formation of transition metal-doxorubicin complexes inside liposomes. *Biochim Biophys Acta* 2002;1565:41.
- Wehrli FW, Shaw D, Kneeland JB. *Biomedical magnetic resonance imaging: principles, methodology, and applications*. New York: Virchow; 1988.
- Morgan L, Nolle A. Proton spin relation in aqueous solutions of paramagnetic ions II:  $Cr^{+++}$ ,  $Mn^{++}$ ,  $Ni^{++}$ ,  $Cu^{++}$ , and  $Gd^{++}$ . *J Chem Phys* 1959;31:365.
- Liang Z-P, Lauterbur PC. *Principles of magnetic resonance imaging: a signal processing perspective*. New York: SPIE Optical Engineering Press; IEEE Press; 2000.
- Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, Needham D, Thrall DE. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. *Clin Cancer Res* 2000;6:3748-3755.
- Leander P, Mansson S, Ege T, Besjakov J. CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model. *Acta Radiol* 1996;37:242-249.
- Niesman MR, Bacic CG, Wright SM, Swartz HJ, Magin RL. Liposome encapsulated  $MnCl_2$  as a liver specific contrast agent for magnetic resonance imaging. *Invest Radiol* 1990;25:545-551.
- Schwendener RA, Wuthrich R, Duewell S, Wehrli E, von Schulthess GK. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. *Invest Radiol* 1990;25:922-932.
- Suga K, M MP, Ogasawara N, Okazaki H, Matsunaga N. Potential of Gd-DTPA-mannan liposome particles as a pulmonary perfusion MRI contrast agent: an initial animal study. *Invest Radiol* 2001;36:136-145.
- Unger E, Fritz T, Shen DK, Wu G. Manganese-based liposomes. Comparative approaches. *Invest Radiol* 1993;28:933-938.
- Chu WJ, Simor T, Elgavish GA. In vivo characterization of Gd(BME-DTTA), a myocardial MRI contrast agent: tissue distribution of its MRI intensity enhancement, and its effect on heart function. *NMR Biomed* 1997;10:87-92.
- Unger E, Shen DK, Wu GL, Fritz T. Liposomes as MR contrast agents: pros and cons. *Magn Reson Med* 1991;22:304-308; discussion 313.
- Bacic G, Niesman MR, Bennett HF, Magin RL, Swartz HM. Modulation of water proton relaxation rates by liposomes containing paramagnetic materials. *Magn Reson Med* 1988;6:445-458.
- Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. *Cancer Res* 2001;61:3027-3032.
- Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. *Cancer Res* 2000;60:6950-6957.
- Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. *Cancer Res* 2000;60:4440-4445.
- Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. *Cancer Res* 2000;60:1197-1201.
- Cheung BC, Sun TH, Leenhouts JM, Cullis PR. Loading of doxorubicin into liposomes by forming  $Mn^{2+}$ -drug complexes. *Biochim Biophys Acta* 1998;1414:205-216.
- Mayer LD, Hope MJ, Cullis PR, Janoff AS. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. *Biochim Biophys Acta* 1985;817:193-196.
- Fiske CH, Subbarow Y. The colour/metric determination of phosphorus. *J Biol Chem* 2 1925:375-395.
- Qiu H, Cofer C, Hedlund L, Johnson GA. Automated feedback control of body temperature for small animal studies with MR microscopy. *IEEE Trans Biomed Eng* 1997;44:1107-1113.
- Grant JP, Wells SA Jr. Tumor resistance in rats immunized to fetal tissues. *J Surg Res* 1974;16:533-540.
- Takehara Y, Sakahara H, Masunaga H, Isogai S, Kodaira N, Takeda H, Saga T, Nakajima S, Sakata I. Tumour enhancement with newly developed Mn-metalloporphyrin (HOP-9P) in magnetic resonance imaging of mice. *Br J Cancer* 2001;84:1681-1685.
- Fossheim SL, Fahlvik AK, Klaveness J, Muller RN. Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. *Magn Reson Imag* 1999;17:83-89.
- Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. *Cancer Res* 1995;55:3752-3756.
- Unger EC, Shen DK, Fritz TA. Status of liposomes as MR contrast agents. *J Magn Reson Imag* 1993;3:195-198.
- Bulte JW, de Cuyper M, Despres D, Frank JA. Short- vs. long-circulating magnetoliposomes as bone marrow-seeking MR contrast agents. *J Magn Reson Imag* 1999;9:329-335.
- Lokling KE, Skurtveit R, Fossheim SL, Smistad G, Henriksen I, Klaveness J. pH-sensitive paramagnetic liposomes for MRI: assessment of stability in blood. *Magn Reson Imag* 2003;21:531-540.



## Benjamin Logan Viglianti, Ph.D.

Email: blv3@duke.edu

5 Tacoma Ct.  
Durham, NC 27712

Home: (919) 471-8167  
Fax: (919) 684-4003

### Work Experience

#### Summer 1998:

- Chesapeake Biological Laboratories: employed as a process development/quality control engineer in the process development division. I became qualified to enter a Class 100 sterile environment. Within this environment, sterile processing procedure was performed for pharmaceutical drugs made for Phase I and II FDA trials. My responsibility was to take the processing procedure developed by the pharmaceutical company and modify it to allow the desired equipment, and accompanying procedures, to enter and operate within the sterile environment while maintaining quality control.

#### Summer 1997:

- Baltimore Aircoil Company: employed in their R&D department as an engineering intern. I was responsible for assisting the design and construction of a 1/8 scale cooling tower test bed. From this test bed, I developed non-linear computational pressure and thermal models for an existing cooling tower surface. From the models, I was able to evaluate the new fill design in the test bed without building a full scale-cooling tower.

#### Summer 1994-1996:

- Community Pool Services Inc.: became a Red Cross certified lifeguard and was employed as a lifeguard ('95). I was employed as a manager of a three-guard pool in the D.C. metropolitan area ('96).
- L.F. Jennings construction: worked as a labor foreman in the demolition and reconstruction of an existing retail center in the D.C. metropolitan area ('94). L.F. Jennings Construction: worked as a carpenter apprentice and labor foreman constructing a Wal-Mart shopping center in the D.C. metropolitan area ('95).

### Education

#### Duke University: Durham, N.C.:

- Graduated in May 2004 with a Doctorate in Philosophy in Biomedical Engineering. My dissertation was entitled "Chemodosimetry of In-vivo Tumor Liposome/Drug Concentration using MRI." The research included the development of an MR imageable liposomes, the development of an in-vivo MR compatible heating device for a rat flank tumor and the validation of using MRI to dynamically measure the concentration distribution and/or content release from thermal sensitive liposomes in-vivo non-invasively. These liposomes are currently being used to treat prostate and breast cancer, and this method to monitor delivery could be applied, further improve treatment efficacy.
- Graduated in December 2000 with a Masters of Science in Biomedical Engineering. Masters research focused on selective surface modification of materials to enhance cell adhesion. Attachment of endothelial cells was explored on spatial addressable protein patterned substrates through the use of self-assembled monolayers.

#### Lafayette College: Easton, Pa.:

- Graduated in May 1994 as a Chemical Engineering with Honors and a curriculum emphasis in Biochemical Engineering, a cumulative GPA of 3.4, and a major GPA of a 3.6. Upon graduation I have accumulated, a total of 152 credits with 15 or more credits in biology, math, and history.
- Achieved significant results in an honors thesis project on biologically produced co-polymers. Co-polymers were produced with bacteria grown in a 1-L bioreactor. Their physical structures were determined with the use of <sup>1</sup>H-NMR. Thermal properties, glass transition temperatures, and heats of fusion were determined with DSC and provided results contradictory to literature. These results suggested the polymers formed were block co-polymer or polymer blends instead of random co-polymers as was stated by previous researchers.

### Organizations:

- An active member of the American Institute of Chemical Engineers since 1994.
- An active member of the Biomedical Engineers Society since 1998.
- An active member of the Radiation Research Society since 2001.

### Publication:

Fellowships and Grants:

- Department of Defense Breast Cancer Research Program (BCRP) of the US Army Medical Research and Materiel Command's Office of the Congressionally Directed Medical Research Programs (CDMRP), DOD Breast Cancer Research Program DAMD17-03-1-0348- "Predicting Drug Concentration Distribution Using a Validated Finite Element Model in Locally Advanced Breast Cancer"

Papers:

- "Spreading diagrams for the optimization of quill pin printed microarray density," Jason T. Smith, Benjamin L. Viglianti, and W. Monty Reichert: *Langmuir* 2002, 18 (16): 6289-6293
- "Carcinogenic effect of hyperthermia," Mark W. Dewhirst, Michael L. Michiels, and Benjamin L. Viglianti: accepted *International Journal of Hyperthermia* 19 (3): 236-251 May-June 2003
- "Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia," Mark W. Dewhirst, Benjamin L. Viglianti, Margaret Hanson, Michael Lora-Michiels, and P. Jack Hoopes 19 (3): 267-294 May-June 2003
- "In-vivo Monitoring of Tissue Pharmacokinetics of Liposome/Drug using MRI: Illustration of Targeted Delivery," Benjamin L. Viglianti, Sheela A. Abraham, Charles R. Michelich, Pavel S. Yarmolenko, James R. MacFall, Marcel B. Bally, Mark W. Dewhirst: *In Press: Magnetic Resonance in Medicine* 51:1153-1162 (2004)
- "Role of Hyperthermia in Regional Alkylating Agent Chemotherapy," Abdel-Wahab, OI, Grubbs, E, Viglianti, BL, Cheng, TY, Ueno, T, Ko, S, Rabbani, Z, Curtis, S, Fruitt, SK, Dewhirst, MW, Tyler, DS., *Clinical Cancer Research* (In Press)

Patents:

- Patent Pending: "Methods and compositions for blood pool identification, drug distribution quantification and drug release verification," Benjamin L. Viglianti, Mark W. Dewhirst, James R. MacFall, and Zeljko Vujaskovic

Conferences:

- "In-vivo monitoring of real time tissue pharmacokinetics of liposome/drug concentration using MRI," Benjamin L. Viglianti, Sheela A. Abraham, James R. MacFall, Marcel B. Bally, Mark W. Dewhirst *Radiology* 225: 647-648 Suppl. S NOV 2002
- "Experimental and clinical thermal dose-to-tissue effect information" (Invited Paper), P. Jack Hoopes, Margaret Hanson, Michael Lora-Michiels, Benjamin L. Viglianti, and Mark W. Dewhirst, *Proceeding of SPIE* vol. 4954, January 26-27, 2003
- "Spatial relationship between tumor perfusion and endogenous glucose distribution," Schroeder T, Richardson R, Larrier N, Viglianti B, Rabbani ZN, Vujaskovic Z, Dewhirst MW, 12th International Congress of the Radiation Research Society (ICRR) in Brisbane, Australia, Aug 17-22, 2003
- "Role of Hyperthermia in Regional Alkylating Agent Chemotherapy," Abdel-Wahab, O, Grubbs, E, Cheng, TY, Viglianti, BL, Ueno, T, Curtiss, SR, Fruitt, SK, Colvin, OM, Dewhirst, MW, Tyler, DS *Annals Of Surgical Oncology*, 11 (2): S79-S80 Suppl. S FEB 2004